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Abstract
Background—Difficulties in emotion processing and poor social function are common to bipolar
disorder (BD) and major depressive disorder (MDD) depression, resulting in many BD depressed
individuals being misdiagnosed with MDD. The amygdala is a key region implicated in processing
emotionally salient stimuli, including emotional facial expressions. It is unclear, however, whether
abnormal amygdala activity during positive and negative emotion processing represents a persistent
marker of BD regardless of illness phase or a state marker of depression common or specific to BD
and MDD depression.
Methods—Sixty adults were recruited: 15 depressed with BD type 1 (BDd), 15 depressed with
recurrent MDD, 15 with BD in remission (BDr), diagnosed with DSM-IV and Structured Clinical
Interview for DSM-IV Research Version criteria; and 15 healthy control subjects (HC). Groups were
age- and gender ratio-matched; patient groups were matched for age of illness onset and illness
duration; depressed groups were matched for depression severity. The BDd were taking more
psychotropic medication than other patient groups. All individuals participated in three separate 3T
neuroimaging event-related experiments, where they viewed mild and intense emotional and neutral
faces of fear, happiness, or sadness from a standardized series.
Results—The BDd—relative to HC, BDr, and MDD—showed elevated left amygdala activity to
mild and neutral facial expressions in the sad (p < .009) but not other emotion experiments that was
not associated with medication. There were no other significant between-group differences in
amygdala activity.
Conclusions—Abnormally elevated left amygdala activity to mild sad and neutral faces might be
a depression-specific marker in BD but not MDD, suggesting different pathophysiologic processes
for BD versus MDD depression.
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There is increasing recognition of the need to identify pathophysiologic processes underlying
key behavioral abnormalities in psychiatric disorders as a first step toward improving
diagnostic accuracy and novel treatment developments for these disorders (1). This is
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particularly relevant to the study of bipolar disorder (BD) depression, where difficulties in
emotion processing and poor social function are common to major depressive disorder (MDD)
depression, resulting in many BD depressed adults being misdiagnosed with MDD, leading to
suboptimal treatment and poor outcome (2). A large number of studies highlight the amygdala
as a key neural region in the processing of emotionally salient stimuli (3–5). Neuroimaging
studies have therefore begun to focus on examination of amygdala activity in BD and MDD
depression (6–8).
There are several questions that remain unanswered, however, regarding amygdala dysfunction
in BD and MDD depression. First, it is unclear whether abnormal amygdala activity to
emotional facial expressions is a persistent marker of BD during both remission and depression
or whether abnormal amygdala activity to these stimuli is a state marker of depression, common
to or differentiating BD and MDD depression. Earlier studies suggested elevated amygdala
activity to happy and fearful facial expressions in remitted, depressed, and hypomanic BD
adults (9). Later studies did not, however, demonstrate abnormal amygdala activity to either
negative (fearful, disgust, sad) or positive (happy) emotional facial expressions in remitted or
stabilized BD adults (BDr) (10–13). Similarly, recent studies reported no abnormality in
amygdala activity to fearful, angry, or sad facial expressions in depressed BD adults (BDd)
(14,15). In depressed adults with MDD, studies reported abnormally elevated amygdala
activity to masked, covertly presented fear, happy, and neutral facial expressions (16–18);
increased amygdala blood flow at rest (19); and pretreatment abnormalities in capacity of
amygdala activity, the response elicited by the difference between baseline and all facial trials
taken together, to sad and neutral emotional expressions (20). Other studies, however, reported
no increases in amygdala activity to happy, sad, or fearful facial expressions, even in a
subliminal condition, in depressed adults with recurrent MDD (21–24). Major depressive
disorder might, therefore, be characterized by abnormally increased baseline amygdala
activity, resulting in no further increase in activity to emotional stimuli versus baseline.
These discrepant findings regarding amygdala activity to facial expressions in BDr, BDd, and
MDD patients likely result from the employment of different paradigms and different
neuroimaging measures across the aforementioned studies. No studies directly compared
amygdala activity in BDd, BDr, and MDD depressed individuals, however. Such a study would
be particularly important to understanding likely pathophysiologic processes that might
differentiate BD from recurrent MDD depression.
Second, it is unclear whether abnormally elevated amygdala activity occurs predominantly to
negative or to positive emotional facial expressions in BD and recurrent MDD. Although
previous studies reported abnormally elevated amygdala activity to both positive and negative
emotional facial expressions in BDr patients (21) and in remitted, depressed, and hypomanic
adults with BD (9), studies in depressed adults with recurrent MDD reported abnormally
elevated amygdala activity mainly to negative emotional facial expressions (16,17,20). Some
findings suggest abnormally elevated amygdala activity to positive emotional facial
expressions in depressed adults with MDD, however (16).
Additionally, although studies in healthy adults reported amygdala activity to neutral faces
(25–28) and one study in youth with BD reported that neutral faces assessed as hostile were
associated with abnormally elevated amygdala activity relative to healthy youth (29), there
have been no studies in adults with mood disorders that focused on examination of amygdala
activity to neutral faces. Although we previously showed increasing magnitude of striatal
activity to facial expressions of increasing intensity of sadness in depressed individuals with
MDD (22), few studies in BD and recurrent MDD patients examined amygdala activity to
different mild and intensely emotional facial expressions.
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We therefore first aimed to examine the extent to which abnormally elevated amygdala activity
to emotional facial expressions was one of the following three possibilities: 1) a persistent
marker of BD during remission and depression, 2) a state marker of depression in both BD and
recurrent MDD, or 3) a specific marker of depression in either BD or recurrent MDD. We
secondly aimed to examine whether abnormally elevated amygdala activity occurred mainly
to negative or to positive emotional facial expressions in each disorder. Our third aim was to
examine the extent to which abnormally elevated amygdala activity would be elicited by
emotional facial expressions other than those displaying prototypical emotion: mild intense
and neutral facial expressions. Extant data did not allow us to make specific hypotheses related
to these aims, because no study has yet directly compared amygdala activity to facial
expressions of different intensities of emotional facial expressions in BDr, BDd, and depressed
individuals with recurrent MDD. We recruited BDr, BDd, and depressed MDD individuals
and a group of age-and gender ratio-matched healthy control participants (HC). We employed
a well-validated facial expression processing paradigm involving displays of negative (fear,
sad) and positive (happy) facial expressions as important signals of socially relevant emotions
of social approval (happy), external threat (fear), and internal distress (sad) of both prototypical
(intense) and mild intensities of each emotion, together with neutral expressions.
Methods and Materials
Participants
Sixty right-handed, native English-speaking individuals were recruited: 30 adults with
recurrent BD type 1, 15 in depressed episode (BDd), and 15 in remission (BDr); 15 individuals
with recurrent MDD in depressed episode, diagnosed according to DSM-IV criteria and the
Structured Clinical Interview for DSM-IV, Research Version (SCID-P); and 15 HCs. The four
groups were age- and gender-matched. The three patients groups were also matched for age of
illness onset and illness duration (Table 1). Most patients were medicated: two BDd patients,
two recurrent MDD patients, and one BDr patient were medication-free.
Medication load, an index that reflects the number and dose of different medications for each
individual (the greater the number and dose of the medication, the greater the medication load;
Supplement 1), was computed for all patients. The three patient groups differed on medication
load [F(2,42) = 4.8; p = .013]: BDd and BDr patients had more medication load than MDD
depressed individuals [t(28) = 3.1; p = .005 and t(28) = 2.4; p = .024, respectively], but BDd
and BDr patients did not differ on medication load [t(28) = .9; p = .4]. The three patient groups
differed in depression severity: BDd and MDD depressed individuals each had higher
depression severity measured on the 25-item Hamilton Rating Scale for Depression (HRSD-25)
than BDr patients [t(14.865) = 12; p < .001 and t(14.936) = 14.25; p < .001, respectively], but
depressed groups did not differ on depression severity [t(28) = 1.3; p = .2]. Reported degree
of freedom reflects significance of the Levene’s test for equality of variances.
All patients had experienced at least two episodes of illness in the last 4 years. Nearly 30% of
recurrent BD and 20% of recurrent MDD patients had lifetime alcohol/illicit substance abuse/
dependence (Table 1) but had not been abusing or dependent on alcohol/illicit substances for
at least 2 months before scanning.
All participants were aware of the purpose of the study and gave written informed consent
before participation in the study. The University of Pittsburgh Institutional Review Board
approved the study protocol.
Exclusion criteria included history of head injury (from medical records and participant report),
systemic medical illness, cognitive impairment (score <24 Mini-Mental State Examination),
premorbid IQ estimate <85 (North American Adult Reading Test) (30), Axis-II borderline
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personality disorder, current alcohol/illicit substance dependence, and general exclusion
criteria for magnetic resonance imaging. For HC, current or previous alcohol and illicit
substance abuse and previous alcohol/illicit substance dependence (determined by SCID-P,
saliva, and urine screen) and previous personal or family history of psychiatric illness in first-
and second-degree relatives were further exclusion criteria.
Paradigm
All individuals participated in three separate 6-min, well-validated event-related experiments
(viewing fear, sad, and happy faces). Each experiment involved viewing 20 mild (50%) and
20 intense (100%) emotional faces and 20 neutral faces from a standardized series (31). Each
facial expression was presented for 2 sec, with an interstimulus interval (ISI) of variable
duration, according to a Poisson distribution (mean ISI = 4.9 sec) (31). Participants were asked
to label the emotion of each face in each experiment (fear, sad, or happy) by moving either the
index (emotional faces) or middle finger (neutral faces) of the right hand to ensure that attention
was directed to the emotional content of the face.
Functional Neuroimaging Data Analyses
Data were preprocessed and analyzed with statistical parametric mapping software (SPM5;
http://www.fil.ion.ucl.ac.uk/spm). Data for each participant were first corrected for differences
in acquisition time between slices; realigned and unwarped, co-registered, normalized, and
spatially smoothed.
A first-level fixed-effect model was constructed for each experiment with three emotion
intensities (neutral, mild, intense) entered as separate conditions in an event-related design with
fixation cross as baseline in the design matrix. Movement parameters from the realignment
stage were entered as covariates of no interest to control for subject movement. Trials were
modeled with the Canonical hemodynamic Response Function. The three intensities were then
entered into second-level analyses with the relevant t-contrast images (intense happy [or sad,
or fear] > baseline; mild happy [or sad, or fear] > baseline; and neutral > baseline).
Three separate (one for each experiment) second-level random-effects group analyses were
conducted on the t-contrast images generated in the previous single-subject analyses in a 4
(group) × 3 (emotion intensity condition) repeated-measures analysis of variance to identify
neural activity in our a priori amygdala region of interest, as defined in the Wake Forest Toolbox
PickAtlas Talairach Daemon template (32). To control for multiple statistical testing we
maintained a cluster-level false positive detection rate at p < .05 by using a voxel threshold of
p < .05 with a cluster ( ) extent empirically determined by Monte Carlo simulations
implemented in AlphaSim of 8 voxels, which accounted for spatial correlations between blood
oxygen level dependent (BOLD) signal changes in neighboring voxels. Post hoc analyses with
independent t tests in SPSS 15.0 for Windows (SPSS, Inc., Chicago, Illinois) were performed
to examine any significant main effect of group or group × emotion intensity interaction upon
amygdala activity in each significant cluster with the mean BOLD signal extracted from β
images derived in the first level analysis. We used Bonferroni correction to correct for multiple
comparisons as appropriate.
Exploratory Analyses of Relationships Between Amygdala Activity and Demographic,
Clinical, and Task Performance Variables
We explored possible relationships between amygdala BOLD response in BDd, BDr, and
depressed recurrent MDD individuals and the following variables: age, age of illness onset,
illness duration, depression severity measured with the HRSD-25, medication load
(Supplement 1), taking versus not taking each psychotropic medication subclass, and comorbid
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alcohol/illicit substance abuse. We used a statistical threshold of p < .05 in these exploratory
analyses.
Results
Face Emotion Labeling Accuracy
The BDd were less accurate than HC groups (but not other groups) when labeling the emotion
of faces during the happy experiment (Table 1). No between-group differences in emotion-
labeling accuracy were observed during the sad and fear experiment (Table 1).
Neuroimaging Data Analyses
Between Group Differences in Amygdala Activity
Happy Experiment: There was no main effect of group or group × emotion intensity
interaction on activity in right or left amygdala.
Fear Experiment: There was a significant group × emotion intensity interaction in the left
amygdala [F(6,168) = 2.81; p = .012,  = 8 voxels]. Post hoc analyses revealed a trend increase
only in left amygdala activity to mild fear expressions in BDd versus recurrent MDD
individuals (Table 2).
Sad Experiment: There was a significant main effect of group in the left amygdala (Figure
1). Post hoc analyses indicated significantly greater left amygdala activity in BDd versus BDr
patients and versus depressed recurrent MDD individuals over all emotional intensities and a
trend increase in mean left amygdala activity that only just failed to meet the strict significance
threshold in BDd versus HC (Figure 1, Table 2). Further analyses revealed that the significant
increase in left amygdala activity in BDd patients versus BDr and depressed recurrent MDD
individuals was evident to mild sad and neutral expressions (Figure 1, Table 2). Analysis of
the female subgroup confirmed abnormally elevated left amygdala activity specific to BDd
patients (Table S5 in Supplement 1).
Relationships Between Demographic, Clinical, and Task Performance Variables
and Amygdala Activity—We restricted these analyses to our significant findings, which
were in the sad experiment. The BDd patients showed significant negative correlations between
left amygdala activity to intense sad facial expressions and illness duration and medication
load (Table 3). The BDr patients showed a significant positive correlation between emotion
labeling accuracy and mean left amygdala activity to all facial expressions (Table 3) and
specifically between mild left amygdala activity and mild sad labeling accuracy. The BDr
patients taking antidepressant medication, versus those not taking antidepressant medication,
showed significantly greater left amygdala activity to all facial expressions and to mild sad and
neutral facial expressions but did not differ in sad emotional labeling accuracy. Recurrent MDD
individuals showed significant positive correlations between left amygdala activity to mild sad
facial expressions and age at scan and age of illness onset (Table 3).
Healthy control subjects did not show any significant relationship among BOLD, age, and
accuracy in either the sad or fear experiment (Table S4 in Supplement 1).
Exploratory whole brain analyses revealed a group × emotion interaction in the left amygdala
during the sad experiment. Post hoc analysis confirmed increased activity in BDd patients
(Table S5 and Table S6 in Supplement 1).
Almeida et al. Page 5
Biol Psychiatry. Author manuscript; available in PMC 2010 April 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Discussion
The main aim of this study was to examine whether abnormally elevated amygdala activity to
different negative and positive emotional facial expressions represented a persistence marker
of BD during both depression and remission or a state marker of depression common to both
or specific to either BD or recurrent MDD depression. We also aimed to examine amygdala
activity to both negative and positive emotional facial expressions and to neutral and mild as
well as intense facial expressions. We showed abnormally elevated left amygdala activity that
was specific to BD depressed individuals and elicited by all facial expressions in the sad
experiment, in particular, by mild sad and neutral facial expressions. Elevated left amygdala
activity specific to BDd patients was confirmed by whole brain exploratory analysis and when
focusing in the female subgroup only (Table S5 in Supplement 1).
Our finding of a bipolar depression-specific pattern of abnormally elevated amygdala activity
is interesting, given the inconsistent findings in the literature regarding amygdala activity in
BDr, BDd, and depressed adults with recurrent MDD (9,10,12,14,16,17,20–22,33). There are
several points to highlight in these previous studies, however. First, no previous study directly
compared amygdala activity to different emotional facial expressions in BDd, BDr, and
depressed adults with recurrent MDD. Second, the discrepancy of these findings might relate
to the use of different paradigms and different neuroimaging measures across the studies. Third,
although previous studies of depressed individuals with recurrent MDD reported elevated
amygdala activity mainly to negative emotional facial expressions (16,17,20), there are points
to consider about these studies. In two of these studies (16,17), facial expressions were
presented covertly in a backward masking paradigm; furthermore, elevated left amygdala
activity was observed to happy, fearful, and neutral masked facial expressions in one of these
studies (16). The backward masking procedure might have made these emotional facial
expressions appear more ambiguous and potentially threatening, which might in turn have
contributed to the elevated amygdala activity observed in depressed recurrent MDD relative
to healthy individuals in this previous study. In another study, greater capacity of amygdala
activity to sad facial expressions was demonstrated in depressed individuals with recurrent
MDD (20), but the extent to which this relates to greater magnitude of amygdala activity to
negative emotional expressions remains unclear. Additional studies reported relationships
between pretreatment amygdala activity to emotional facial expressions and symptom
improvement after treatment (34) and depression symptom severity (22) but did not show
abnormally elevated amygdala activity to these facial expressions in depressed MDD adults
relative to HC. Furthermore, we previously showed elevated ventral striatal but not elevated
amygdala activity to sad facial expressions in depressed individuals with recurrent MDD
(22). These previous findings, together with the present findings of abnormally elevated
amygdala activity in BDd but not BDr patients or depressed individuals with recurrent MDD,
therefore suggest that abnormally elevated amygdala activity might represent a
pathophysiological process specific to BD but not recurrent MDD depression.
The use of an overt emotion labeling task in the present study might have contributed to our
findings of abnormally elevated amygdala activity only in BDd patients and not in depressed
recurrent MDD individuals or BDr patients. Previous reports indicate that, unlike implicit
emotion processing such as gender labeling, explicit emotion labeling of facial expressions is
not consistently associated with robust amygdala activity in HC, because it might be dependent
on explicit appraisal and reappraisal processes supported by lateral prefrontal cortex rather
than the amygdala (35). Our finding of elevated amygdala activity in BDd patients in the present
study might therefore reflect aberrant amygdala–lateral prefrontal cortical functional coupling
during appraisal of emotion in BDd patients but not depressed individuals with recurrent MDD
or BDr that could be examined in future studies with functional connectivity analyses. It is also
possible that, with larger numbers of participants, we would have been able to demonstrate
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significant increases in amygdala activity in depressed individuals with recurrent MDD and
BDr relative to HC during the sad- or other emotion-experiments. The effect sizes in the
significant post hoc pairwise between-group comparisons for the sad experiment (Cohen’s d
= 1.02 – d = 1.97) are similar to the effect sizes in previous between-group comparisons of
amygdala activity (e.g., Lawrence et al. [21]), suggesting that our study was powered to detect
significant between group differences in amygdala activity during each emotion experiment
consistent with previous findings.
Regarding our second aim, we found a negative-emotion–specific pattern of abnormally
elevated amygdala activity in BDd patients to all faces in the sad experiment relative to other
groups. This finding is consistent with previous cognitive theories of depression proposing a
negative emotion attentional bias in depression in general and in particular to self-relevant
negative emotional material (36), such as mood-congruent, sad facial expressions in the present
study. Our findings suggest, however, that the negative emotional attentional bias in BD and
recurrent MDD depression might be associated with different pathophsysiologic processes in
the two disorders. In further support of the latter point, we recently demonstrated that recurrent
MDD depression is associated with a top-down, negative connectivity between orbital medial
prefrontal cortex (OMPFC) and amygdala to positive (happy) facial expressions, suggesting
an “inhibition” of amygdala activity to positive emotional facial expressions in recurrent MDD
depression, whereas BD depression is associated with a disconnectivity between OMPFC and
amygdala to happy faces (37). We also previously demonstrated an attentional bias away from
labeling facial expressions mild happy rather than a bias toward labeling facial expressions as
sad in recurrent MDD depression (38). These, together with the present findings, therefore
suggest that recurrent MDD depression might be characterized more by an inhibitory response
to positive emotional facial expressions that might lead to an attentional bias away from these
stimuli rather than by attentional bias toward negative emotional facial expressions. By
contrast, our previous and present findings in BDd patients of OMPFC–amygdala
disconnectivity to happy faces and elevated amygdala activity to mood-congruent sad facial
expressions suggest that BD depression might be characterized by an attentional bias to
negative, mood-congruent expressions rather than an attentional bias away from happy faces.
The BDd patients showed, with regard to our third aim, elevated amygdala activity to neutral
and mild rather than intense sad facial expressions relative to BDr and depressed individuals
with recurrent MDD. Mild emotional and neutral facial expressions are often perceived as more
ambiguous and potentially threatening than intense facial expressions (38,39) and might elicit
amygdala activity because of the proposed role of this structure in processing ambiguity and
potential threat (40). Although BDd patients accurately labeled facial expressions in the sad
and fear experiments, abnormally elevated amygdala activity to mild sad and neutral facial
expressions might therefore suggest abnormal perception of potential threat in these faces in
BDd patients, consistent with previous observations of abnormally elevated amygdala activity
to neutral facial expressions appraised as hostile in BD youth (29). Employment of subjective
ratings of threat and hostility during facial expression emotion labeling in future studies in BD
could help clarify this.
The laterality of our amygdala findings in BDd patients is interesting. Previous studies report
sustained response of the left rather than right amygdala during fearful facial expression
processing in HC (41,42), whereas studies that manipulated displays of facial expressions to
prevent subjective awareness of these stimuli, most frequently through a backward masking
procedure, reported right-sided lateralization of amygdala activity (43). In our analyses, we
fitted a hemodynamic response function to the presentation of each facial stimulus that models
sustained rather than initial transient activity to all stimuli of a given emotion intensity in each
experiment. Our finding of a between-group difference in left- rather than right-sided amygdala
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activity during facial emotion labeling therefore supports a more sustained and evaluative
response of the left than right amygdala during emotion processing.
Although there was no significant effect of group on emotion labeling in the sad experiment,
all participants demonstrated a minimum of 54% and a maximum of 82% accuracy rather than
nearer to 100% accuracy on labeling emotional faces. This was likely due to the known
difficulty in accurately labeling mild emotional facial expressions from the facial expression
series employed in our study (44). Previous studies in MDD depressed individuals indicated
facial emotional expression labeling impairments in MDD and BD depressed individuals
(45–47). The more difficult nature of the facial expression-labeling task we used might have
masked any between-group difference on task performance, because all individuals had some
difficulty with emotion face labeling.
Our exploratory analyses indicated few significant relationships between left amygdala activity
to facial expressions in the sad experiment and clinical variables. The BDd patients with longer
illness duration and higher medication load had lower amygdala activity to intense sad but not
mild sad or neutral facial expressions. Previous findings in MDD indicate a reduction in
amygdala capacity and activity after antidepressant treatment (20,34), which parallel our
finding in medicated BDd patients in the present study. It is therefore possible that the combined
effects of psychotropic medication and longer illness duration might have contributed to
normalization of elevated left amygdala activity, at least to intense sad facial expressions, in
BDd patients. The possible perception of the more ambiguous mild sad and neutral facial
expressions as potentially threatening by BDd patients might have accounted for the absence
of effects of illness duration and medication upon left amygdala activity to these stimuli.
Greater left amygdala activity in BDr patients was associated with more accurate emotion
labeling of all facial expressions, especially the more ambiguous mild sad facial expressions.
The BDr patients taking antidepressant medication also showed greater left amygdala activity
to the more ambiguous mild sad and neutral facial expressions although did not differ from
HC on magnitude of left amygdala activity to these expressions. Together, these findings might
suggest that, in BDr patients, greater left amygdala activity during emotion labeling of mild
sad and neutral facial expressions—which in turn is more significant in BDr patients potentially
more vulnerable to depression (i.e., BDr patients taking vs. BDr patients not taking
antidepressant medication)—might represent a persistent, attentional bias to sad faces
associated with more accurate sad emotion labeling that represents a vulnerability marker to
depression in BDr patients. Depressed individuals with recurrent MDD showed a positive
correlation between left amygdala activity and age at scan and with age of MDD onset,
suggesting that older individuals with later age of illness onset had a pattern of left amygdala
activity more similar to BDd patients.
There were limitations to the present study. We did not include a group of euthymic individuals
with a history of recurrent MDD and therefore did not examine whether amygdala activity to
emotional facial expressions differentiated remitted and depressed phases of recurrent MDD.
Future studies could therefore compare depressed with recovered individuals with a history of
MDD. We deliberately focused examination on the amygdala in this first study comparing
BDd, BDr, and depressed individuals with recurrent MDD, but clearly other neural regions are
implicated in emotion processing (6). Many patients were medicated, especially depressed
patients, because of the need for medication in these severely depressed individuals. We
showed normalizing rather than confounding effects of medication upon amygdala activity in
BDd patients, however, suggesting that medication was unlikely to have contributed to the
elevated left amygdala activity in the sad experiment in BDd patients. There were relatively
small numbers of men in each group, and we did not obtain accurate information regarding the
amount of current or past use of nicotine in study participants. Greater numbers of men and
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tobacco-using histories could be included in future studies of BDr, BDd, and MDD depressed
individuals.
Our findings suggest that abnormally elevated left amygdala activity to sad faces might
represent a depression-specific marker of BD but not recurrent MDD depression that is
unrelated to medication. Despite the very similar clinical presentation of BD and MDD
depression, different pathophsysiologic processes might be associated with these two
disorders. Together with emerging data indicating different patterns of abnormal effective
connectivity during happy emotion processing in BD and MDD depression (37), the present
data highlight the potential future use of neuroimaging in the search for biological markers to
help improve accuracy of early diagnosis of BD depression.
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Figure 1.
(A) Anatomical location of left amygdala activity where the main effect of group was
statistically different during the sad experiment. Foci of significance were overlaid on sagittal,
coronal, and axial brain slices spatially normalized into the Montreal Neurologic Institute
coordinates system (x = −18, y = − 3, z = −18; cluster size = 11 voxels; F = 4.96; p = .003,
corrected for multiple comparisons). (B) Mean left amygdala activity to faces in the sad
experiment in each group; *trend toward significance; **significant comparison after
controlling for multiple comparisons. (C) Activity in the left amygdala in response to intense
and mild sad and neutral faces in each group. BOLD, blood oxygen level dependent; BDd,
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bipolar disorder patients in depressed episode; BDr, bipolar disorder patients in remission;
MDD, major depression disorder patients in depressed episode; HC, healthy control
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